Terry Horgan, the patient who was undergoing gene editing treatment being conducted by Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition, died during the landmark Crispr study.
The only participant in a new study employing a gene-editing technique has passed away, and the trial's organisers are now attempting to determine what caused his death.
Terry Horgan, a 27-year-old who had Duchenne muscular dystrophy, died last month, according to Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition.
Little is known about how he passed away, although it happened during one of the initial trials of a gene editing treatment made just for him. It's generating concerns about the potential of such treatments generally, which have raised hopes among many families dealing with rare and fatal diseases.
“This whole notion that we can do designer...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
